Clinical Trials List
2025-08-18 - 2030-06-30
Phase I/II
Recruiting4
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.09
Secondary carcinoid tumors of other sites
ICD-10C7B.1
Secondary Merkel cell carcinoma
ICD-10C7B.8
Other secondary neuroendocrine tumors
ICD-10C80.0
Disseminated malignant neoplasm, unspecified
ICD-10D3A.8
Other benign neuroendocrine tumors
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.0
Disseminated malignant neoplasm
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- Chun-Hui Lee Division of Hematology & Oncology
- 黃盈慈 Division of Hematology & Oncology
- Chih-Chieh Yen Division of Hematology & Oncology
- 黃怡菁 Division of Hematology & Oncology
- 劉奕廷 Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- Chia-Jui Yen Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- 黃怡璇 Division of Hematology & Oncology
- 鍾秉軒 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shang-Fu Hsu Division of Thoracic Medicine
- Kai-Ling Lee Division of Thoracic Medicine
- Mei-Chuan Chen Division of Thoracic Medicine
- 高冠鈞 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳冠任 Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- Chun-Bing Chen Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- 賴盈傑 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
180 participants